首页 正文

SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β1-adrenergic antagonism for the treatment of movement and neuropsychiatric disorders

{{output}}
Unmet needs in hyperkinetic movement disorders (HMDs) within neuropsychiatric conditions include better treatments for HMDs in complex disorders like Huntington's disease (HD), Tourette syndrome and psychiatric comorbidities like tardive dyskinesia. The sympt... ...